Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) fell 2.9% during mid-day trading on Friday . The stock traded as low as $14.49 and last traded at $14.64, with a volume of 191,787 shares trading hands. The stock had previously closed at $15.07.

Several research firms have recently issued reports on ADMS. Noble Financial began coverage on shares of Adamas Pharmaceuticals in a research report on Friday, June 17th. They issued a “buy” rating and a $25.00 price target on the stock. Credit Suisse Group AG reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 22nd. Mizuho reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Thursday, June 23rd. JMP Securities reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 15th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $44.00 target price on shares of Adamas Pharmaceuticals in a report on Tuesday, June 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $32.00.

The company’s market cap is $323.67 million. The company has a 50-day moving average price of $14.23 and a 200 day moving average price of $15.29.

An institutional investor recently bought a new position in Adamas Pharmaceuticals stock. Ameriprise Financial Inc. purchased a new position in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 64,978 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,840,000. Ameriprise Financial Inc. owned about 0.35% of Adamas Pharmaceuticals as of its most recent SEC filing.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.